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Abstract: The goal of this study was to investigate the toxicokinetic characteristics of aflatoxin G1 
(AFG1) in broiler chickens and the effect of calcination of a Tunisian montmorillonite clay on the in 
vivo absorption of AFG1. In this study, broiler chickens were randomly distributed into four groups 
of 10 animals. Group 1 was administered AFG1 (2 mg/kg body weight (BW)) by single intravenous 
injection (IV), group 2 received an intra-crop bolus (PO) of AFG1 without any clay, group 3 was 
dosed AFG1 PO together with an oral bolus of purified clay (CP), and group 4 received AFG1 PO 
with an oral bolus of calcined clay. A significant difference in the area under the curve (AUC0-t) was 
observed for group 4 (6.78 ± 4.24 h*ng/mL) in comparison with group 2 (12.83 ± 4.19 h*ng/mL). A 
significant reduction of the oral bioavailability of AFG1 was observed for group 4 (7.61 ± 4.76%) 
compared with group 2 (14.40 ± 4.70%), while no significant effect was observed of CP. In this 
experiment, no phase I nor phase II metabolites of AFG1 were observed. These findings confirm 
that calcination of the purified montmorillonite clay enhances the adsorption of AFG1 in the 
gastrointestinal tract after oral administration, thereby reducing its bioavailability, thus reducing its 
toxic effects. 
Keywords: AFG1; toxicokinetics; LC-MS/MS; LC-HRMS; calcination; montmorillonite clay; broiler 
chicken 
Key Contribution: A toxicokinetic study of AFG1 with or without calcined and purified 
montmorillonite clay was performed in broiler chickens. The calcined clay has successfully 
improved the adsorption of AFG1 in the gastrointestinal tract after oral administration. 
 
1. Introduction 
Mycotoxins are secondary fungal metabolites present on a multitude of crops. Incorrect storage 
conditions, stress conditions during pollination, warm ambient temperatures and drought conditions 
during the growing season, and insect damage can lead to aflatoxins (AFs) contamination of food 
and feed commodities [1]. Aflatoxins are difuranocoumarin derivatives produced mainly by 
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Aspergillus flavus and Aspergillus parasiticus strains and can contaminate many different crops, 
particularly maize, groundnuts, and wheat [2–4]. Aflatoxin contamination of feed and animal 
products can differ depending on geographical location, country development level, and climatic 
conditions. Aflatoxin production mainly occurs in regions with tropical or subtropical climates [5]. 
Among the various types of AFs, which include aflatoxin B1 (AFB1), aflatoxin B2 (AFB2), aflatoxin 
G1 (AFG1), and aflatoxin G2 (AFG2), AFG1 is the second most toxic aflatoxin after AFB1 [6–8]. 
Moreover, the International Agency for Research on Cancer has classified AFG1 as a group 2B toxin, 
stating that this may be carcinogenic to humans [9]. Aflatoxins form colorless to pale-yellow crystals. 
These crystals are intensely fluorescent in ultraviolet light, emitting blue (AFB1 and AFB2) or green 
(AFG1) and green-blue (AFG2) fluorescence [10]. In poultry, the effects of aflatoxins include a.o. 
hepatotoxicity, impaired productivity, decreased egg production, inferior eggshell quality, lower 
carcass quality, and increased susceptibility to other diseases [11]. Aflatoxicoses reduce the 
performance of broiler chickens due to decreased feed intake, increased feed conversion, reduced 
weight gain [12], and altered visceral organ weights [13–15]. Feeding a high dose (3.5 mg AFs/kg 
feed) of an AFs mixture (79% AFB1, 16% AFG1, 4% AFB2, and 1% AFG1) to broilers significantly 
reduced their body weight and increased their liver and kidney weights [16]. Moreover, at low 
chronic doses of AFB1 (0.03 mg/kg of feed), a reduction of body weight gain of 30% has been observed 
[17]. Oral administration of AFG1 can induce hyperplastic lesions and adenocarcinoma of the lung 
in NIH mice [18]. AFG1 also caused the development of liver tumors in experimental animals but 
generally at a lower incidence than AFB1 [19]. Ma et al. [20] studied the characteristics of the 
interaction between AFB1/AFG1 and calf thymus DNA in a pH 7.4 Tris-HCl buffer. The results 
demonstrated that both AFB1 and AFG1 bound to calf thymus DNA, forming complexes through 
hydrogen bonding.  
To protect poultry and other livestock from the deleterious effects of these toxins, various post-
harvest intervention strategies have been developed. One such approach is adding mycotoxin 
detoxifying agents to the feed [21–23]. These detoxifiers can be divided into two different classes, 
namely mycotoxin binders and mycotoxin modifiers. Mycotoxin binders are able to bind mycotoxins, 
reducing their oral bioavailability by the formation of a non-resorbable binder–toxin complex in the 
intestinal tract that is eliminated through the feces [24,25]. The adsorption processes between 
mycotoxin and adsorbing agents are interactions between the surface of the adsorbent (e.g., 
mycotoxin binder) and the adsorbate (e.g., toxin). The adsorption capacity of clay minerals depends 
on their physico-chemical properties [22]. Adsorption to clays is not limited to the surface of the clay 
particles but extends also to the interlayer spaces of the clay. These spaces can increase when the clay 
swells, thereby increasing the number of binding sites [26]. Among the mycotoxin binders, 
phyllosilicate clays are the largest group and have been used in numerous research trials [27–29]. 
Different studies demonstrated that mineral adsorbents including bentonite, zeolite, 
montmorillonite, and hydrated sodium calcium aluminosilicate can bind or adsorb mycotoxins to 
their interlayer spaces, external surface, and edges [21,30–32]. Montmorillonite, an aluminum silicate, 
is characterized by a permanent negatively charged surface and exchangeable cations in the 
interlayer space. Montmorillonite clays have excellent effectiveness in binding polar mycotoxins such 
as aflatoxins, and consequently reducing their toxicity [33–35]. The physico-chemical properties of 
clay minerals can be affected by various treatments, including thermal treatment, acid activation, 
pillaring, organic modification with polymers, or cation and anion exchange [36–38]. These modified 
clays might bind some of the mycotoxins better than the untreated clay [39,40]. Recently, it has been 
observed that calcination of purified Tunisian montmorillonite clay (CC) at 550 °C enhanced the in 
vitro adsorption efficacy for AFB2, AFG1, AFG2, and zearalenone (ZEN) compared to the non-heat-
treated purified form (CP) of the same clay. The binding capacity of AFB1 was almost 100% for both 
purified and calcined clay [38]. Calcination is a process in which clay minerals are heated to different 
temperatures. In vitro studies are used as a screening tool for the potential of substances to act as 
mycotoxin binder. However, in vitro studies do not adequately mimic the conditions in the digestive 
tract, the differences between target animals and their metabolism, and, therefore, cannot be used to 
demonstrate efficacy under practical conditions. Some in vivo experiments are thus necessary for 
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their assessment [41]. The in vivo efficacy of a mycotoxin detoxifier can be evaluated by measuring 
the impact on unspecific parameters such as animal performance, histological changes, and 
hematological parameters [42–44]. Nevertheless, the European Food Safety Authority (EFSA) asserts 
that toxicokinetic studies have to be performed in order to evaluate the oral bioavailability and the 
absorption/excretion of mycotoxins mixed with the binder [41]. According to the EFSA, one of the 
most relevant parameters for evaluating the effectiveness of these products against mycotoxins is the 
plasma concentration of these toxins or their main metabolites or interaction products with 
macromolecules such as nucleic acids or proteins [45]. 
To estimate the health risk in affected animals and also to evaluate the possible carry-over of 
AFs into tissues and products derived from animals, the knowledge of the adsorption, distribution, 
metabolism, and excretion (ADME) process of these mycotoxins is fundamental. The results of an in 
situ perfusion technique employed on rats demonstrated that absorption of AFs in the small intestine 
is a very fast process that pursues first-order kinetics, with an absorption rate constant (ka) of 5.84 ± 
0.05, 4.06 ± 0.09, 2.09 ± 0.03, and 1.58 ± 0.04 h-1, respectively, and with absorption half-lives of 7.12 
(AFB1), 10.24 (AFB2), 19.90 (AFG1), and 26.30 (AFG2) min [46]. Similarly, following oral 
administration of AFB1 (0.25 mg/kg BW) to rats, the plasma concentration indicates a rapid 
absorption, with a maximum concentration at 10 min [47]. After intravenous injection (IV) 
administration of 14C-labelled AFB1 in mice, rats, and monkeys, the excretion of the toxin is high 
during the initial 24 h following single intravenous administration. However, the total recovery of 
the administered AFB1 is between 72% and 80% during the first 100 h after the IV injection [48]. After 
oral administration of 14C-labelled AFB1 to laying hens, 71% might be recovered within 7 days post-
administration. In the same study, only 28% of the administered dose of AFB1 could be recovered 
during the first 24 h [49]. In this regard, Hussain et al. [50] demonstrated that feeding of three levels 
of AFB1 (1.6, 3.2, and 6.4 mg/kg BW) to broiler chicks of three different ages (7, 14, and 28 days) for 7 
days results in a slow residues clearance after the withdrawal of AF-contaminated feed. AFB1 is 
detectable in the liver and muscles for a long period when the birds are younger and when they are 
fed high AFB1 dietary levels. This suggests that birds develop a more sufficient mechanism of 
metabolizing AFB1 with increasing age.  
To the best of our knowledge, no in vivo toxicokinetic studies of AFG1 with or without 
mycotoxin detoxifier in broiler chickens have been published, and only one study explored the effect 
of calcination on mycotoxin binding [31]. The aim of this study was to investigate a) the toxicokinetic 
parameters of AFG1 and b) the effect of calcination of purified montmorillonite clay collected from 
Jebel Aïdoudi (El Hamma, Gabes, Tunisia) on different toxicokinetic parameters of AFG1 in broiler 
chickens. First, a UHPLC-MS/MS method for the quantitative determination of AFG1 in broiler 
chicken plasma was optimized and validated. Second, a toxicokinetic study with AFG1 was done in 
broiler chickens. Finally, the LC-MS/MS method was transferred to a ultra-high-performance liquid 
chromatography-high-resolution mass spectrometry (UHPLC-HRMS) instrument, and plasma 
samples were analyzed to evaluate the presence of possible phase I and phase II metabolites of AFG1.  
2. Results 
2.1. UHPLC-MS/MS Plasma AFG1 Method Validation 
The in-house UHPLC-MS/MS method was sensitive for AFG1. For the calibration model, a 
linear, 1/x2 weighed, fitting was applied. The results for linearity (r and g) and sensitivity (limit of 
quantitation (LOQ) and limit of detection (LOD)) were summarized in Table 1. Linear matrix-
matched calibration curves were reached (range of 0.50–200 ng/mL) with r = 0.9987 ± 0.0008 (n = 3) 
and g = 4.50 ± 1.48% (n = 3) values falling within the limits of ≥0.99 and ≤20%, respectively. The LOQ 
was set at 0.50 ng/mL, whereas the LOD was found to be 0.16 ng/mL. Furthermore, the within-day 
and between-day precision and accuracy fell within the acceptance criteria specified in the guideline 
VICH GL49 [51], and are given in Supplementary Table S2. Moreover, the reconstitution solvent was 
injected after the highest calibrator sample in each analytical batch. In some, but not all, solvent 
samples, a small peak at the elution zone of AFG1 was observed, indicating a mean carry-over of 
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0.06% on the UHPLC-MS/MS instrument. Moreover, the response of the eventual peak at the elution 
zone of AFG1 fell below 20% of that of the corresponding peak in the LOQ samples. The specificity 
of the method was evaluated by the analysis of a blank plasma sample in each analytical batch. In 
some blank plasma samples, a small peak at the elution zone of AFG1 was observed, but the response 
was below 20% of that of the LOQ value (0.5 ng/mL). 
In Figure S1, UHPLC-MS/MS chromatograms are shown of the analysis of a blank sample (A), a 
blank sample spiked at the LOQ level of 0.5 ng/mL (B), and two real samples that were taken 10 min 
after the IV (C) and 30 min after the intra-crop bolus (PO) (D) of 2 mg/kg BW of AFG1 to two chickens.  
Table 1. Results of the evaluation of linearity (goodness-of-fit coefficient (g), correlation coefficient 
(r)), limit of quantitation (LOQ), and limit of detection (LOD) for the analysis of aflatoxin G1 (AFG1) 














0.0008 0.50 0.16 
a Acceptance criteria: g ≤ 20%, r ≥ 0.99. 
2.2. Toxicokinetic Characteristics Of Afg1 
No clinical symptoms of intoxication were observed following the administration of 2 mg/kg 
BW of AFG1 PO or IV to the broilers. Plasma AFG1 concentration–time profiles, obtained after 
UHPLC-MS/MS analysis for oral and IV administrations in broiler chickens, are shown in Figure 1.  
Results of the mean toxicokinetic parameters of AFG1 are summarized in Table 2. Following oral 
administration, plasma AFG1 concentration increased rapidly in broiler chicken plasma to attain a 
maximum at 0.50 ± 0.30 h. Furthermore, AFG1 was rapidly eliminated after PO (T1/2el = 1.36 ± 0.55 h) 
as well as after IV (Tl/2el = 0.50 ± 0.20 h) administration. The mean Vd and Cl values were 22.52 ± 20.32 
L/kg and 28.50 ± 18.22 L/h/kg, respectively, after IV administration. Mean area under the curve 
(AUC)0-t values were 12.83 ± 4.19 and 89.06 ± 36.94 h*ng/mL following PO and IV administration, 
respectively. Therefore, the oral bioavailability of AFG1 was 14.40 ± 4.70%.  
 
Figure 1. 3D molecular structure (insert) and mean plasma concentration–time profile of AFG1 after 
oral (intra-crop bolus (PO)) and intravenous (IV) administration of 2 mg/kg bodyweight to broiler 
chickens (n = 10). Values are presented as the mean + or − SD. Plasma concentrations of AFG1 were 
























Time p. a. (h)
AFG1 IV AFG1 PO
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Table 2. Mean toxicokinetic parameters of AFG1 determined after intravenous (IV) and oral (PO) 
administration (2 mg/kg BW) to broiler chickens, either with purified clay (CP, n = 10) or with calcined 
clay (CC, n = 10). 
Toxicokinetic Parameters               Route of Administration 
 IV  PO 
   PO PO + CP PO + CC P-value 
AUC0-t (h*ng/mL) 89.06 ± 36.94  12.83 ± 4.19a 11.36 ± 5.10ab 6.78 ± 4.24b 0.026 
AUC0-∞(h*ng/mL) 89.86 ± 36.73  15.10 ± 4.82a 14.73 ± 5.08ab 9.06 ± 5.03b 0.041 
Cmax (ng/mL) _  11.01 ± 5.32 10.41 ± 7.50 13.59 ± 14.95 0.760 
C0 (ng/mL) 274.62 ± 144.49  _ _ _ _ 
Tmax (h) _  0.50 ± 0.30 0.48 ± 0.36 0.48 ± 0.34 0.987 
kel (h-1) 1.53 ± 0.42  0.57 ± 0.17 0.35 ± 0.26 0.55 ± 0.36 0.158 
T1/2el (h) 0.50 ± 0.20  1.36 ± 0.55 2.15 ± 1.61 2.49 ± 0.30 0.498 
Cl (L/h/kg) 28.50 ± 18.22  _ _ _ _ 
Vd (L/kg) 22.52 ± 20.32  _ _ _ _ 
F (%) 100  14.40 ± 4.70a 12.75 ± 5.73ab 7.61 ± 4.76b 0.026 
AUC0−t, area under the plasma concentration−time curve from time 0 to last concentration > LOQ; 
AUC0−∞, area under the plasma concentration−time curve from time 0 to infinity; Cmax, maximal 
plasma concentration; C0, plasma concentration at time 0; tmax, time to maximal plasma concentration; 
kel, elimination rate constant; t1/2el, elimination half-life; Cl, total body clearance; Vd, volume of 
distribution; F, oral bioavailability. Values in each row indicated by different letters (a,b) are 
significantly different (p ≤ 0.05). Values are presented as the mean ± SD. 
2.3. UHPLC-HRMS Analysis 
The plasma extracts were also injected onto a UHPLC-HRMS instrument to investigate the 
presence of eventual phase-I and phase-II metabolites for which no analytical standards are available. 
The same analytical column and mobile phases were used, as for the UHPLC-MS/MS analysis, but a 
slower gradient was applied (see Table 4). As can be seen in Figure S2-B, this resulted in an increase 
in the retention time of AFG1 from ∼4.4 min (UHPLC-MS/MS) to ∼9.4 min (UHPLC-HRMS). 
No peak at the elution zone of AFG1 was observed in the extracted ion chromatogram (XIC, 0.05 
Da) at m/z = 329.0661 of a plasma sample that was taken prior to IV administration of AFG1 to a 
chicken (Figure S2A). The identity of the chromatographic peak at 9.4 min in a plasma sample of the 
same chicken, which was taken at 10 min after IV administration of AFG1 (dose: 2 mg/kg BW), could 
be confirmed based on the elemental composition of the ion with m/z = 329 in the low energy mass 
spectrum (proposed elemental composition: C17H12O7, observed accurate mass: m/z = 329.0676, mass 
error: 1.5 mDa or 4.5 ppm; Figure S2C) and the observed major fragment ions with m/z = 243.0646 
and 311.0546 in the high-energy mass spectrum (Figure S2D).  
An untargeted approach was used to investigate the presence of metabolites, which means that 
certain transformations were added to the pathway profiling processing method, such as oxidation 
(+ O), reduction (+ H2), desaturation (− H2), hydration (+ H2O), sulfation (+ SO3), oxidation + 
desaturation (+ O − H2), dehydration (− H2O), dihydrodiol formation (+ H2O2), glucuronidation (+ 
C6H8O6), and glutathione conjugation (+ C10H15N3O5S). In Figure S3, XICs of the analysis of plasma 
samples that were taken at 10 min after IV administration (panel A) and at 30 min after the PO 
administration of AFG1 (panel B), are shown. As can be seen, AFG1 could be detected and confirmed 
in both plasma samples (see Table S3). No additional peaks were observed in the plasma sample after 
PO administration, indicating the absence of metabolites. In the plasma sample that was taken after 
IV administration, AFG1-related peaks were observed in the XIC at m/z = 311.0556 and 331.0818, 
which could be attributed to in-source fragmentation of AFG1 and to the 14C-isotope of the [M-H] + 
ion of AFG1. The identification of the peaks in the other XICs could not be confirmed, indicating the 
no AFG1-metabolites were present in this plasma sample. The same results were observed for all 
other plasma samples of the same chickens. 
Quantification of the AFG1 concentration with the UHPLC-HRMS instrument was performed 
in plasma samples of 2 chickens after IV and PO administration using a targeted approach, i.e., the 
theoretical exact mass that was calculated on the basis of the chemical formula (m/z = 329.0661) was 
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added to the processing method. As can be seen in Figure S4, a good correlation (r2 ≥ 0.9597) was 
found between the results obtained using both analytical techniques.  
2.4. Efficacy of the Calcinated Clay 
Figure 2 illustrates the plasma concentration–time profile of AFG1 after oral administration of 
AFG1 alone or in combination with CP and CC. The mean AUC0-t was significantly lower after PO + 
CC administration compared to PO administration (p = 0.026) (Table 2). There was an average 
decrease of AUC0-∞ of approximately −47 % after CC administration compared to PO administration. 
Consequently, administering a calcined montmorillonite clay to broiler chickens resulted in a 
significantly decreased F of AFG1 (7.61 ± 4.76%) compared to birds that did not receive any mycotoxin 
detoxifier (PO, 14.40 ± 4.70%) (p = 0.026). 
 
Figure 2. Mean plasma concentration–time profile of AFG1 in broiler chickens after oral (PO) 
administration (2 mg/kg BW), either with purified clay (CP, n = 10, orange curve) or with calcined 
clay (CC, n = 10, grey curve). Each profile represents the mean of 10 animals. Values are presented as 
the mean + or − SD. Plasma concentrations of AFG1 were quantified using UHPLC-MS/MS. 
3. Discussion 
In this study, an in vivo toxicokinetic study was performed in order to extend the knowledge of 
the absorption and oral bioavailability of AFG1 in broiler chickens and to evaluate the effect of 
calcination of montmorillonite clay on different toxicokinetic parameters of AFG1. The findings 
indicated that AFG1 is rapidly absorbed after oral administration (Tmax = 0.50 ± 0.30 h). Similar 
research using murine models indicate that the absorption of AFs is a very fast process that follows 
first-order kinetic [46,52]. Corcuera et al. [47] found that the absorption of AFB1 in rats is very fast 
and that the molecule is rapidly metabolized in the liver. After exposure of rats to a single 
intratracheal or oral [H3]AFB1 dose, a peak of AFB1 plasma concentration was measured after one 
and three hours [53]. Gallo et al. [54] showed that AFs are quickly absorbed through the 
gastrointestinal tract of cows. Although rapid, AFG1 in the present study had a low oral 
bioavailability of 14.40 ± 4.70%. Besides the rapid but limited absorption, AFG1 was rapidly 
eliminated after PO (T1/2el = 1.36 ± 0.55 h) as well as after IV (Tl/2el = 0.50 ± 0.20 h) administration. Both 
clearance and volume of distribution were high with a mean (± SD) Cl and Vd AFG1 of 28.50 ± 18.22 
(L/h/kg) and 22.52 ± 20.32 (L/kg) in chickens, respectively. These results are in discordance with other 
studies that found that the elimination of AFs from the body is slower as compared to other 
mycotoxins [55]. In the case of laying hens, only 28% of the hens orally administered 14C-labelled 
AFB1 could be recovered during the first 24 h, and 71% were recovered within 7 days post-
administration [49]. After IV administration of 14C-labelled AFB1 in mice, rats, and monkeys, the 
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tissue concentration of AFG1. In this context, Hussain et al. [50] showed that after 2 to 3 days of 
exposure of broiler chickens to a diet containing 0, 1.6, 3.2, and 6.4 mg AFB1/kg, AFB1 could be 
detected in livers of birds exposed to 1.6 mg/kg and higher for more than one week. 
The developed UHPLC-MS/MS method used an Oasis® Ostro 96-well plate (Waters, Zellik, 
Belgium) for sample clean-up, allowing protein precipitation and phospholipid removal in one 
action. Hence, it was possible to extract 96 plasma samples simultaneously. By combining this simple 
and straightforward sample preparation procedure with a gradient elution of 10 min on the UHPLC-
MS/MS instrument, a large number of samples (n ≥ 96) could be analyzed within a 24 h period, which 
was an advantage if a large number of samples had to be analyzed as a part of toxicokinetic studies. 
The method was successfully validated and allowed the quantification of AFG1 in broiler plasma 
samples over a range of 0.5–200 ng/mL. The LOQ value of 0.5 ng/mL was low enough to allow 
accurate quantification of AFG1 in plasma samples that were taken from broiler chickens after IV or 
PO administration (dose: 2 mg/kg BW).  
The knowledge of metabolites of AFG1 in broiler chicken is limited; therefore, the plasma 
samples obtained during the toxicokinetic study after oral and intravenous administration were 
analyzed using UHPLC-HRMS to identify the presence of phase I and II metabolites. The UHPLC-
MS/MS method was transferred to a UHPLC-HRMS instrument with some modifications in the 
chromatographic gradient to increase the retention time of AFG1 and allow a better separation of 
potential metabolites. Using a non-targeted pathway profiling approach, no relevant metabolites 
were found by UHPLC-HRMS. This can be attributed to the short exposure to AFG1. In contrast, in 
a recent paper, Slobodchikova et al. [56] characterized phase I and phase II glucuronide metabolites 
of in vitro microsomal incubation. These authors showed the presence of one hydroxy metabolite of 
AFG1, which can be identified as AFGM1 metabolite. In addition, the good correlation between 
quantitative results obtained with both the UHPLC-MS/MS and UHPLC-HR-MS instruments 
demonstrated the potential of the latter technique for use in the field of quantitative analysis in the 
future.  
In the current study, AFG1 was also administered with purified and calcined montmorillonite 
to test the effectiveness of calcination of the clay mineral in adsorbing AFG1. A significant decrease 
of 47% in AUC was observed after the CC administration compared to PO administration indicating 
that the calcined clay was effective in binding AFG1. Lauwers et al. [57] stated that the detoxifier was 
effective in binding mycotoxins when the AUC was significantly lower when compared to the AUC 
without detoxifier in plasma and urine, whereas the kel was not significantly different between the 
three groups. In addition, no significant difference was observed in maximum concentration and time 
to maximum concentration. A recent study showed a significant influence of a mycotoxin-detoxifying 
agent on the AUC of AFB1 in broiler chickens [57]. In the same study, the authors did not observe 
any significant difference in Cmax and Tmax. In our study, the F value was significantly decreased by 
47% after the administration of calcined clay. This could be attributed to the adsorption of AFG1 by 
the calcined clay in the gastrointestinal tract. Previously, it has been demonstrated by in vitro study 
that calcination improved the adsorption of AFs and mainly of AFG1 and AFG2 at pH 3 and pH 7 of 
the gastrointestinal tract [38]. The in vitro binding affinity is consistent with the in vivo results 
observed here and supports the hypothesis that calcination improves the aflatoxin-binding capacity 
of montmorillonite clay, which is a key property involved in the toxicity-alleviating effects.  
4. Conclusions 
In this research, the toxicokinetic characteristic and bioavailability of AFG1 in broiler chicken 
were interpreted for the first time. AFG1 is rapidly absorbed after oral administration and rapidly 
eliminated after oral as well as IV administration. The oral bioavailability was low (18.43%), which 
may be due to the rapid transport of the toxin through the alimentary tract of the chickens. In 
addition, the in vivo efficacy of calcined montmorillonite in binding AFG1 was demonstrated for the 
first time. Calcination reduced the bioavailability, thus avoiding its toxic effects. Notwithstanding the 
high adsorption of AFs by calcinated clay, little is known about the unspecific binding, which is a 
major consideration. Mycotoxin binders may indeed also adsorb nutrients, micronutrients, and/or 
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veterinary drugs [58,59]. Therefore, in vivo safety testing of the studied binder is needed. Moreover, 
research evaluating the effect of calcination on other types of clay on other mycotoxins should be 
done. 
5. Materials and Methods  
5.1. Standard, Reagents, and Solutions 
The standard of AFG1, used for both plasma analysis and the animal experiment, was obtained 
from Fermentek Ltd. For the LC-MS/MS analysis, the internal standard (IS) 13C17-AFG1 was obtained 
as a 0.5 µg/mL solution in acetonitrile (ACN) from Biopure (Tulln, Austria). All standards were kept 
at ≤−15 °C. Methanol (MeOH) and ACN were of ultra-liquid chromatography (ULC-MS) grade and 
were purchased from Biosolve (Valkenswaard, The Netherlands). UPLC-grade water was obtained 
from a Milli-Q Reference A+ system (Merck, Overijse, Belgium). Formic acid (FA) of analytical grade 
was purchased from VWR (Leuven, Belgium). Dimethyl sulfoxide (DMSO) used for the animal 
experiment was of analytical grade and was obtained from Filterservice (Eupen, Belgium). Oasis® 
Ostro protein precipitation and phospholipid removal 96-well plates (25 mg), 96-well collector plates, 
and polypropylene mat caps for 96-well plates were purchased from Waters (Zellik, Belgium). A 
Tunisian clay was collected from Jebel Aïdoudi (El Hamma, Gabes, Tunisia) and was purified to 
obtain the purified clay (CP) as described [38]. The thermally treated clay (CC) was obtained by 
calcination of the purified clay at 550 °C for 5 h. The chemical composition of both clays did not 
change after calcination and was characterized by a high calcium content and a low percentage of 
sodium oxide. The analysis of the studied clay with X-ray diffraction exhibited that the studied clay 
was composed mostly of calcic smectite [38]. 
5.2. Preparation of Standard Solutions 
For the animal trial, a stock solution (SS) of AFG1 (8 mg/mL) was prepared in DMSO. For the 
plasma analysis, a SS of AFG1 (0.2 mg/mL) was prepared in ACN. Working solutions of AFG1 (WS) 
at concentrations of 1000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/mL, and 0.1 ng/mL were prepared by 
appropriate dilution of the SS in ACN. For the IS, a working solution (WSIS) containing 13C17-AFG1 at 
a concentration of 10 ng/mL was prepared in ACN. The SS and all the WS were stored at ≤−15 °C.  
5.3. Animals and Toxicokinetic Study Design 
A total of forty, 3 weeks-old healthy broiler chickens (Ross 308, ♂/♀, 20/20) were obtained from 
a commercial breeder (Moerbeke, Belgium). A lighting cycle of 18 h of light and 6 h of darkness was 
applied. The temperature regime was adjusted to the changing needs of the animals according to 
their age. During the one-week acclimatization period, all animals were group-housed in a floor pen 
of 4 m2. Mycotoxin control feed and water were given ad libitum during the acclimatization and 
experimental period.  
Commercially available broiler mash feed was obtained from AVEVE (Merksem, Belgium). This 
feed was analyzed for the presence of the following mycotoxins: 3 and 15-acetyldeoxynivalenol (3- 
and 15-ADON), deoxynivalenol (DON), T2 and HT2-toxin, AFB1, AFB2, AFG1, and AFG2, fumonisin 
B1 + B2 (FB1 and FB2), zearalenone (ZEN), nivalenol (NIV), cytochalasin E, and ochratoxin A (OTA), 
by a multi-mycotoxin liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
(Primoris, Zwijnaarde, Belgium). This control feed contained 125 µg/kg of DON and 44.4 µg/kg of 
FB1 + FB2; the levels were below the maximum guidance level allowed by the EU regulations [60]. 
After one-week acclimatization, animals were weighed and subsequently randomly distributed 
based on sex and body weight into four groups of 10 animals (♂/♀, 5/5). During the experimental 
phase of the study, animals were housed per group in a floor pen of 2 m². Eight hours before the 
mycotoxin bolus administration, the animals were deprived of feed, until 3 h post-administration.  
Animals of the first group were administered a bolus AFG1 (2 mg/kg BW) by IV injection in the 
wing vein. The second group was administered AFG1 (2 mg/kg BW) orally by an intra-crop bolus 
(PO) followed by 4 mL of sterile distilled water (PO control group). The third group was administered 
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first a bolus of AFG1 PO (2 mg/kg BW) then an intra-crop bolus of purified clay (CP, 1 g/kg BW, 
suspended in 2 mL of sterile distilled water), followed by 2 mL of sterile distilled water to flush the 
crop tube. The fourth group received first a bolus of AFG1 PO (2 mg/kg BW) then an intra-crop bolus 
of calcinated clay (CC, 1 g/kg BW, suspended in 2 mL of sterile distilled water), followed by 2 mL of 
sterile distilled water to flush the crop tube. Before the administration of the mycotoxin, the PO and 
IV AFG1 bolus solution were prepared instantaneously by further dilution of the AFG1 SS with water 
(PO) or physiological saline (IV). After administration of AFG1 with or without clay, 0.5 mL of blood 
was collected via the leg vein at 0 (just before administration), 0.08, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 
6, 8, 12, and 24 h post-administration in heparinized tubes (Vacutest Kima, Novolab, Geraardsbergen, 
Belgium). The samples were centrifuged (3724 × g, 10 min, 4 °C), and aliquots of plasma (100 µL) 
were stored at ≤−15 °C until analysis.  
The animal experiment was approved by the ethical committee of the Faculty of Veterinary 
Medicine and the Faculty of Bioscience Engineering of Ghent University (EC 2019/70, approval date: 
17 October 2019).  
5.4. Plasma AFG1 Analysis 
5.4.1. Sample Pre-Treatment 
To 100 µL of chicken plasma, 25 µL of IS working solution (10 ng/mL) and 100 µL of ACN were 
added, followed by a vortex mixing step and further equilibration at room temperature for 5 min. 
The samples were loaded onto an Oasis® Ostro 96-well plate (25 mg), followed by the addition of 300 
µL of 1% FA in ACN. The sample was mixed by aspiration using a pipette (5 times) and passed 
through the 96-well plate while the vacuum was applied (15 mm Hg) for 5 min. The filtrate was 
collected in a 96-well collector plate and evaporated under a gentle nitrogen stream (∼40 °C). The dry 
residue was reconstituted in 200 µL of water/methanol (MeOH) (50/50, v/v), followed by vortex 
mixing for 15 sec. After covering the 96-well collector plate with a polypropylene mat cap, an aliquot 
5.0 µL was injected onto the UHPLC-MS/MS instrument. For samples with a concentration out of the 
calibration curve, the injection volume was reduced to 0.5 or 1.0 µL.  
5.4.2. UHPLC-MS/MS Analysis  
The UHPLC-MS/MS instrument consisted of an Acquity UPLC® H-Class Quaternary Solvent 
Manager and Flow-Through-Needle Sample Manager with temperature-controlled tray and column 
oven (Waters, Zellik, Belgium). The column was an Acquity UPLC® HSS T3 (Waters, Zellik, Belgium), 
100 mm × 2.1 mm i.d., dp: 1.8 µm, associated with an Acquity HSS T3 1.8 µm Vanguard pre-column 
(Waters, Zellik, Belgium). Chromatography was performed using water and methanol as mobile 
phase A and B, respectively, in gradient elution as displayed in Table 3. The flow-rate of the mobile 
phase was set at 0.3 mL/min. The temperatures of the column oven and autosampler tray were set at 
40 °C and 8 °C, respectively. 
The UHPLC column effluent was sent to a Xevo TQ-S® MS/MS system, equipped with an 
electrospray ionization (ESI) probe that was operated in the positive mode (all from Waters, Zellik, 
Belgium). The UHPLC eluent was directed to the mass spectrometer from 3.0 to 6.0 min, using a 
divert valve. MS/MS instrument parameters were determined by direct infusion of WS of 100 ng/mL 
of AFG1 and the IS, respectively, at a flow rate of 10 µL/min and in combination with the mobile 
phase A/B (50/50, v/v) at a flow-rate of 200 µL/min. The following parameters were used: capillary 
voltage: 3.2 kV, source offset: 50 V, source temperature: 150 °C, desolvation temperature: 600 °C, 
desolvation gas: 800 L/h, cone gas: 150 L/h, nebuliser pressure: 6.9 bar, low mass resolution 1 and 2: 
2.8, high mass resolution 1 and 2: 15.00, respectively, ion energy 1 and 2: 0.2 and 0.8, respectively, 
collision gas flow: 0.15 mL/min. 
MS/MS acquisition was performed in the multiple reaction monitoring (MRM) mode and an 
overview of the MRM transitions for AFG1 and the IS is given in supplementary Table S1. Data 
acquisition and processing were performed using the MassLynx v.4.1 software (Waters, Zellik, 
Belgium). 
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Table 3. Gradient elution for the UHPLC-MS/MS separation. 
Time (min) % Mobile Phase A % Mobile Phase B 
0–1.0 80 20 
3.0 - 90 
3.0–7.0 10 90 
7.3 - 90 
7.3–10.0 80 20 
5.4.3. In-House Method Validation 
The developed UHPLC-MS/MS method was validated in-house for AFG1 based on a protocol 
that was previously described by De Baere et al. [61]. Spiked blank plasma samples that were 
obtained from healthy, untreated chickens were used for method validation. The following 
parameters were evaluated: linearity, accuracy, precision, the limit of quantification (LOQ), the limit 
of detection (LOD), and carry-over, according to the recommendations and guidelines defined by the 
European Community and with criteria described in the literature [51,61–65]. 
Linearity: Linearity was evaluated over a concentration range between 0.05 and 200 ng/mL using 
matrix-matched calibration curves. The correlation coefficients (r) and goodness-of-fit coefficients (g) 
were determined and had to comply with the following limits: r ≥ 0.99 and g ≤ 20%, respectively.  
Accuracy and precision: Accuracy and precision were determined by analyzing three sets of 6 
spiked blank samples in the same run at the following concentration levels of AFG1: 0.5 ng/mL, 5.0 
ng/mL, and 50.0 ng/mL. The between-run accuracy and precision were evaluated in a similar way by 
analyzing at least 3 blank samples spiked at the same concentration levels on three different days. 
The acceptance criteria for accuracy were met at all concentration levels (supplementary Table 3). The 
precision was evaluated by the determination of the relative standard deviation (RSD), which had to 
be below the RSDmax value.  
Limit of quantification: The LOQ was established as the lowest point of the calibration curve and 
was set at 0.05 ng/mL. 
Limit of detection: The LOD was calculated as 3 times the standard deviation of the y-intercept 
divided by the average slope of three independent calibration curves.  
Carry-over: The absence/presence of carry-over on the UHPLC-MS/MS instrument was 
evaluated by analyzing the reconstitution solvent injected after the highest calibrator sample. 
Specificity: to investigate the specificity of the analytical method, a blank plasma sample was 
extracted and analyzed in each analytical batch.  
5.5. Plasma Phase I and Phase II Metabolites of AFG1 
UHPLC-HRMS analysis was performed on plasma samples from four animals after PO 
administration and five animals after IV administration. 
The UHPLC-HRMS instrument consisted of an Acquity I-Class UPLC coupled to a Synapt G2-
Si HDMS instrument (Waters, Zellik, Belgium) and was used to identify potential phase-I and phase-
II metabolites of AFG1 in incurred chicken plasma samples. The same analytical column and mobile 
phases were used as described in Table 4. The flow rate was set at 0.3 mL/min. The temperatures of 
the column oven and autosampler tray were 40 °C and 8 °C, respectively. A standard solution of 
AFG1 was infused by a syringe to optimize HR-MS instrument parameters. The following HR-MS 
parameters were finally selected: capillary voltage, 2.70 kV; sampling cone voltage, 30.0 V; source 
offset, 80.00 V; source temperature, 150 °C; desolvation temperature, 550 °C; cone gas flow, 50 L/h; 
desolvation gas flow, 800 L/h; nebulizer gas flow, 6.50 bar; lock spray capillary voltage, 2.0 kV. Data 
acquisition was performed between 0.5 and 11.5 min in the positive ESI ionization mode using MSE 
continuum scanning. The following time-of-flight MS settings were used: low mass, 50 Da; high mass, 
950 Da; scan time, 0.15 s; data format, continuum; collision energy (CE): low energy trap and transfer 
CE: off, high energy trap CE: ramp between 10 to 60 V, transfer CE: off. Leucine encephalin (200 
pg/µL) was used as a lock mass component. The lock spray was acquired, but no correction was 
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applied during HR-MS acquisition. The lock spray settings were: scan time, 0.15 s; interval, 30 s; scans 
to average, 3; mass window, 0.5 Da. Data processing and lock mass correction (m/z 556.2765) was 
performed using the Unify 1.8 software (Waters, Zellik, Belgium). The identification of AFG1 was 
based on retention time (target TR tolerance: 0.1 min) and mass (target mass tolerance: 10 ppm). The 
examination of phase I and phase II metabolites of AFG1 was performed using a pathway profiling 
approach. The following transformations were looked for: oxidation (+ O), reduction (+ H2), 
desaturation (− H2), hydration (+ H2O), sulfation (+ SO3), oxidation + desaturation (+ O − H2), 
dehydration (− H2O), dihydrodiol formation (+ H2O2), glucuronidation (+ C6H8O6), glutathione 
conjugation (+ C10H15N3O5S). 
Table 4. Gradient elution for the UHPLC-HRMS separation. 
Time (min) % Mobile Phase A % Mobile Phase B 
0–2.0 90 10 
4.0 - 30 
4.0–6.0 70 30 
8 - 50 
8.0–10.0 50 50 
12.0 - 70 
12.0–14.0 30 70 
14.2 - 90 
14.2–16.5 10 90 
17.0 - 10 
17.0–20.0 90 10 
5.6. Toxicokinetic and Statistical Analysis 
Non-compartmental toxicokinetic modeling was carried out using Phoenix (Princeton, NJ, 
USA). Plasma concentrations under the LOQ were not considered. The most important toxicokinetic 
parameters were calculated for IV and PO administration: area under the plasma concentration–time 
curve from time 0 to 8 h (AUC0-t), area under the plasma concentration–time curve from 0 to infinity 
(AUC0-∞), maximal plasma concentration (Cmax), plasma concentration at time 0 (C0), time to maximal 
plasma concentration (Tmax), elimination rate constant (kel), elimination half-life (T1/2el), clearance (Cl) 
and volume of distribution (Vd). The absolute oral bioavailability (F), expressed as a percentage, was 
calculated according to the formula:  
F = (AUC0-∞ PO / AUC0-∞ IV) × 100 (1) 
All toxicokinetic parameters were compared with a Tukey HSD test (SPSS 26, IBM, New York, 
NY, USA). The level of significance was set at 0.05. Graphs were obtained with Microsoft Office (office 
365). The 3D molecular structure of AFG1 was obtained with Chem3D v15 (shareware). 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/10/660/s1, Table 
S1: MRM transitions and MS/MS parameters for AFG1 and the internal standard, 13C17-AFG1; Table S2: Results 
of the within-run and between-run precision and accuracy evaluation for the analysis of aflatoxin G1 in chicken 
plasma; Table S3: Results of the investigation of the UHPLC-HRMS extracted ion chromatograms (XIC) of a 
plasma sample taken at (A) 10 min after intravenous administration and (B) 30 min after oral administration of 
2 mg AFG1/kg BW for possible phase I and phase II metabolites; Figure S1: UHPLC-MS/MS chromatogram of 
(A) a blank plasma sample, (B) a blank plasma sample spiked at the LOQ level (AFG1 concentration: 0.50 ng/mL), 
a plasma sample taken at (C) 10 min after intravenous administration (AFG1 concentration : 101.7 ng/mL) and 
(D) 30 min after oral administration of 2 mg AFG1/kg BW (AFG1 concentration : 12.0 ng/mL); Figure S2: UHPLC-
HRMS extracted ion chromatogram (XIC) at m/z = 329.0661 of a plasma sample taken (A) before and (B) at 10 
min after intravenous administration of 2 mg/kg BW, showing a peak of AFG1 at Tr = 9.42 min (concentration : 
89.2 ng/mL); (C) low-energy spectrum of the peak at Tr = 9.42 min, showing the [M-H]+ ion of AFG1 (observed 
accurate mass at m/z = 329.0699, mass error: 1.5 mDa or 4.5 ppm); (D) high-energy spectrum of the same peak, 
showing the two major fragment ions of AFG1 at m/z = 243.0646 and 311.0546; Figure S3: UHPLC-HRMS 
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extracted ion chromatograms (XIC) of a plasma sample taken at (A) 10 min after intravenous administration 
(AFG1 concentration : 89.2 ng/mL) and (B) 30 min after oral administration of 2 mg AFG1/kg BW (AFG1 
concentration : 11.7 ng/mL). The following mass-to-charge (m/z) values, corresponding with the theoretical exact 
mass of the protonated molecular ions [M-H]+, were extracted from the total ion chromatogram: (a) parent AFG1, 
C17H12O7 : 329.0661; (b) oxidation (+ O), C17H12O8 : 345.0610; (c) reduction (+ H2), C17H14O7 : 331.0818: (d) 
desaturation (− H2), C17H10O7 : 327.0505; (e) hydration (+ H2O), C17H14O8 : 347.0767; (f) sulfation (+ SO3), C17H12O10S 
: 409.0229; (g) oxidation + desaturation (+ O− H2), C17H10O8 : 343.0454; (h) dehydration (− H2O), C17H10O6 : 
311.0556; (i) dihydrodiol formation (+ H2O2), C17H14O9 : 363.0716; (j) glucuronidation (+ C6H8O6), C23H20O13 : 
505.0982; (k) glutathione conjugation (+ C10H15N3O5S), C27H27N3O12S ; 618.1394; Figure S4: Correlation between 
the AFG1 plasma concentrations in 2 chickens that received an (A) oral and (B) intravenous administration of 2 
mg/kg BW, after quantitative analysis using the UHPLC-MS/MS and UPLC-HRMS technique, respectively. 
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